When dementia symptoms show up before age 65, or run through several generations of a family, a genetic panel for familial Alzheimer's disease looks at three genes — APP, PSEN1, and PSEN2 — whose mutations directly cause early-onset disease. Before ordering one, the questions that matter most are what the test can rule in or out, who qualifies for coverage, and what a result will actually change about care. A panel answers a narrower question than most families expect: it finds or excludes a specific inherited mutation, not a prognosis. Knowing what to ask before testing — and before acting on a result — keeps the panel useful rather than confusing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does the panel's design match this patient's situation?
- What will a negative result actually mean?
- What will a positive result tell the family — and what won't it tell them?
- Who else in the family should consider testing, and under what conditions?
- Does APOE testing belong in this conversation?
- What should the family ask about the logistics of testing?
- Frequently Asked Questions
Does the panel's design match this patient's situation?
The three-gene panel is built for a specific pattern: dementia onset before age 65, often with a parent or sibling diagnosed at a similarly young age. According to insurer medical policy from BCBS/Avalon, APP, PSEN1, and PSEN2 mutations are autosomal dominant, meaning a single copy inherited from one parent is enough to cause disease, typically with early onset. Ask whether the symptomatic family member's age at onset and family history actually fit that profile.
Insurers generally require either dementia onset at or before 65, or an early-onset presentation where family history is unknown — for example, because the patient was adopted — before they will cover sequencing of APP, PSEN1, and PSEN2, according to a policy summary filed with Louisiana's Medicaid program. A patient diagnosed at 72 with no young-onset relatives is unlikely to meet that bar. If the family's pattern doesn't cleanly match the classic three-gene picture — mixed ages of onset, or dementia alongside other neurological symptoms — ask about a broader panel instead. GeneDx's Dementia Panel sequences 11 genes, including APP, PSEN1, and PSEN2, with an estimated four-week turnaround once the lab begins processing, according to the GeneDx test detail page.
What will a negative result actually mean?
A negative result on the three-gene panel does not rule out a familial cause. Ask the ordering clinician to explain detection rates by gene before treating "negative" as "no inherited risk." Among early-onset familial Alzheimer's cases, PSEN1 mutations are found in roughly 30 to 70 percent, APP in roughly 10 to 15 percent, and PSEN2 in under 5 percent, according to medical policy from Blue Cross NC.
A strong family history with a clean panel still leaves real uncertainty, since a sizable share of genuinely familial cases carry no detectable mutation in these three genes. This matters for how the result gets used with other relatives. A negative finding in the symptomatic patient does not clear younger relatives of risk, and it should not end the conversation about family history — it narrows the explanation, it doesn't close the case.
What will a positive result tell the family — and what won't it tell them?
A positive mutation in APP, PSEN1, or PSEN2 confirms the inherited cause of the patient's dementia. Ask directly what it does not tell the family: the same Blue Cross NC policy notes that a positive result does not predict age of onset, severity, or rate of progression.
A relative who later tests positive for the identical mutation could follow a markedly different course than the person who was tested first. That gap matters when families ask a genetic counselor "how fast will this go" or "when will my child show symptoms" — the panel cannot answer either question, even with a confirmed mutation in hand.
Who else in the family should consider testing, and under what conditions?
A positive result in the symptomatic patient opens the door to predictive testing for relatives who have no symptoms yet. Ask about the specific conditions insurers set: predictive testing of an asymptomatic relative is generally covered only when a causative mutation has already been identified in a first- or second-degree relative, the person being tested is an adult, and they have not already been tested for that gene, according to Blue Cross NC's policy. Genetic counseling before testing is strongly recommended under the same policy, given the implications of a positive result for someone with no symptoms.
- Confirm the exact mutation found in the symptomatic relative before ordering predictive testing — testing an asymptomatic person for the wrong variant wastes the opportunity.
- Ask whether the relative has been tested for that specific gene before; insurers generally won't cover a repeat.
- Raise genetic counseling as a required step, not an optional add-on, before an asymptomatic adult decides to test.
Does APOE testing belong in this conversation?
APOE ε4 is a separate test from the three-gene panel, and it measures something different: risk, not cause. Ask whether anyone is proposing APOE testing, and why. Australia's RACGP guideline states that APOE testing has limited clinical utility for diagnosis and is not recommended in routine clinical practice, according to the RACGP's genomics guideline.
APOE genotyping does have one concrete, current use as symptoms progress and treatment decisions come up: the Alzheimer's Association's appropriate-use recommendations call for APOE genotyping before starting lecanemab, an anti-amyloid drug, to inform discussion of ARIA — amyloid-related imaging abnormality — risk, according to the Alzheimer's Association's lecanemab/APOE toolkit. The genotype changes the actual odds: in the CLARITY-AD trial, ARIA occurred in about 19 percent of lecanemab-treated APOE ε4 heterozygotes versus about 45 percent of ε4 homozygotes, according to a 2025 peer-reviewed review. Ask whether this test is being ordered to answer a diagnostic question, which it can't do well, or a treatment-safety question, which is exactly what it's for.
What should the family ask about the logistics of testing?
Before ordering, ask which lab the panel will run through, since turnaround times and availability differ. Labcorp's APP/PSEN1/PSEN2 next-generation sequencing panel runs 14 to 28 days and is not available in New York state, while PreventionGenetics offers the same three genes at a base price of $990, with a 25 percent surcharge for STAT (expedited) orders, according to Labcorp's test directory and PreventionGenetics' test page.
- Ask which three genes (or, for a broader panel, which additional genes) are actually included, and confirm it matches the clinical picture.
- Ask about turnaround time against any upcoming treatment decision, since a four-week wait on a broader panel can outlast the window for a time-sensitive choice.
- Ask whether the lab serves the patient's state, since at least one major lab panel is unavailable in New York.
- Ask what the surcharge is for an expedited result, and whether the clinical situation actually requires one.
Frequently Asked Questions
Can a negative three-gene panel mean the dementia still runs in the family genetically?
Yes. PSEN1, APP, and PSEN2 together don't catch every familial case, and detection rates vary sharply by gene, so a negative result doesn't rule out an inherited cause.
Does a positive mutation result predict how quickly the disease will progress?
No. Insurer policy on this testing specifically states that a positive result does not predict age of onset, severity, or progression rate, even within the same family.
Is APOE testing the same as the familial Alzheimer's panel?
No. APOE measures risk and is not recommended for routine diagnosis, but it is specifically used before starting the anti-amyloid drug lecanemab to assess ARIA risk.
